Do analysts recommend UPB or APLM?

Upstream Bio currently has a consensus price target of $29.67, indicating a potential upside of 735.68%. Given Upstream Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Upstream Bio is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, UPB or APLM?

Apollomics has higher revenue and earnings than Upstream Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upstream Bio $2.85M 68.22 -$143.44M -$2.90 N/A Apollomics $8.50M 7.41 -$10.94M N/A N/A

Do analysts prefer APLM or IMRX?

Immuneering has a consensus target price of $15.71, indicating a potential upside of 341.41%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, APLM or IMRX?

Apollomics has higher revenue and earnings than Immuneering. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.41 -$10.94M N/A N/A Immuneering N/A N/A -$56.03M -$1.04 N/A

Is APLM or IMRX more profitable?

Apollomics' return on equity of 0.00% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Immuneering N/A -27.15% -25.75%

Do analysts prefer APLM or CAMP?

CAMP4 Therapeutics has a consensus target price of $10.86, indicating a potential upside of 216.53%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CAMP4 Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CAMP4 Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has higher valuation & earnings, APLM or CAMP?

Apollomics has higher revenue and earnings than CAMP4 Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.41 -$10.94M N/A N/A CAMP4 Therapeutics $3.50M 61.50 -$80.40M -$2.32 N/A

Do analysts rate STRO or APLM?

Sutro Biopharma presently has a consensus target price of $49.50, suggesting a potential upside of 349.59%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, STRO or APLM?

Apollomics has lower revenue, but higher earnings than Sutro Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sutro Biopharma $102.48M 1.78 -$191.09M -$11.97 N/A Apollomics $8.50M 7.41 -$10.94M N/A N/A

Is STRO or APLM more profitable?

Apollomics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -395.25% N/A -88.12% Apollomics N/A N/A N/A

Do analysts recommend GALT or APLM?

Galectin Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 198.10%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, GALT or APLM?

Apollomics has higher revenue and earnings than Galectin Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Apollomics $8.50M 7.41 -$10.94M N/A N/A

Is GALT or APLM more profitable?

Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Apollomics N/A N/A N/A

Apollomics (APLM) Competitors

$21.63 +0.31 (+1.45%)

Closing price 10/13/2026 03:58 PM Eastern

Extended Trading

$21.63 0.00 (0.00%)

As of 10/13/2026 04:10 PM Eastern

Compare

APLM vs. UPB, IMRX, CAMP, STRO, and GALT

Should you buy Apollomics stock or one of its competitors? Apollomics's main competitors and comparable companies include Upstream Bio (UPB), Immuneering (IMRX), CAMP4 Therapeutics (CAMP), Sutro Biopharma (STRO), and Galectin Therapeutics (GALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Apollomics compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

19.1% of Apollomics shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Apollomics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Apollomics' return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Apollomics	N/A	N/A	N/A

Upstream Bio currently has a consensus price target of $29.67, indicating a potential upside of 735.68%. Given Upstream Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Upstream Bio is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Upstream Bio has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

Apollomics has higher revenue and earnings than Upstream Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	68.22	-$143.44M	-$2.90	N/A
Apollomics	$8.50M	7.41	-$10.94M	N/A	N/A

In the previous week, Upstream Bio and Upstream Bio both had 1 articles in the media. Upstream Bio's average media sentiment score of 1.82 beat Apollomics' score of 1.07 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Upstream Bio	Very Positive
Apollomics	Positive

Summary

Apollomics beats Upstream Bio on 7 of the 13 factors compared between the two stocks.

How does Apollomics compare to Immuneering?

Apollomics (NASDAQ:APLM) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 14.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Apollomics' return on equity of 0.00% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Immuneering	N/A	-27.15%	-25.75%

Immuneering has a consensus target price of $15.71, indicating a potential upside of 341.41%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Apollomics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Apollomics has higher revenue and earnings than Immuneering.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.41	-$10.94M	N/A	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

In the previous week, Immuneering had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Immuneering and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.07 beat Immuneering's score of 1.05 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Positive
Immuneering	Positive

Summary

Immuneering beats Apollomics on 7 of the 13 factors compared between the two stocks.

How does Apollomics compare to CAMP4 Therapeutics?

Apollomics (NASDAQ:APLM) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

CAMP4 Therapeutics has a consensus target price of $10.86, indicating a potential upside of 216.53%. Given CAMP4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CAMP4 Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Apollomics has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Apollomics' return on equity of 0.00% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

In the previous week, CAMP4 Therapeutics had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for CAMP4 Therapeutics and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.07 beat CAMP4 Therapeutics' score of 0.64 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Positive
CAMP4 Therapeutics	Positive

Apollomics has higher revenue and earnings than CAMP4 Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.41	-$10.94M	N/A	N/A
CAMP4 Therapeutics	$3.50M	61.50	-$80.40M	-$2.32	N/A

Apollomics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

19.1% of Apollomics shares are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Apollomics beats CAMP4 Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Apollomics compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Sutro Biopharma has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

In the previous week, Sutro Biopharma had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Sutro Biopharma and 1 mentions for Apollomics. Sutro Biopharma's average media sentiment score of 1.26 beat Apollomics' score of 1.07 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sutro Biopharma	Positive
Apollomics	Positive

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sutro Biopharma presently has a consensus target price of $49.50, suggesting a potential upside of 349.59%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has lower revenue, but higher earnings than Sutro Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	1.78	-$191.09M	-$11.97	N/A
Apollomics	$8.50M	7.41	-$10.94M	N/A	N/A

Apollomics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Apollomics	N/A	N/A	N/A

Summary

Sutro Biopharma beats Apollomics on 9 of the 14 factors compared between the two stocks.

How does Apollomics compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Galectin Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 198.10%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Apollomics	N/A	N/A	N/A

Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

In the previous week, Galectin Therapeutics had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.07 beat Galectin Therapeutics' score of 0.31 indicating that Apollomics is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Neutral
Apollomics	Positive

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Apollomics has higher revenue and earnings than Galectin Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Apollomics	$8.50M	7.41	-$10.94M	N/A	N/A

Summary

Apollomics beats Galectin Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$62.15M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.64	201.05	19.53
Price / Sales	7.41	1,148.21	561.79	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-7.48	17.13	10.77	6.03
Net Income	-$10.94M	-$22.69M	$3.50B	$380.34M
7 Day Performance	1.64%	-4.40%	-2.89%	-2.34%
1 Month Performance	-9.57%	-12.45%	-7.37%	-5.31%
1 Year Performance	17.36%	7.64%	2.99%	-2.94%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	1.723 of 5 stars	$21.63 +1.5%	N/A	+17.4%	$62.15M	$8.50M	N/A	15
UPB Upstream Bio	2.8037 of 5 stars	$4.59 -0.1%	$29.67 +547.0%	-82.3%	$251.13M	$3.16M	N/A	75	News Coverage Positive News
IMRX Immuneering	2.7187 of 5 stars	$3.86 +0.7%	$15.71 +307.6%	-42.0%	$249.41M	N/A	N/A	57	Positive News
CAMP CAMP4 Therapeutics	3.323 of 5 stars	$3.96 -0.1%	$10.86 +174.5%	-4.5%	$248.49M	$3.50M	N/A	644
STRO Sutro Biopharma	3.6213 of 5 stars	$14.94 +3.4%	$49.50 +231.3%	+32.9%	$248.30M	$102.48M	N/A	128	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. UPB, IMRX, CAMP, STRO, and GALT

How does Apollomics compare to Upstream Bio?

Summary

How does Apollomics compare to Immuneering?

Summary

How does Apollomics compare to CAMP4 Therapeutics?

Summary

How does Apollomics compare to Sutro Biopharma?

Summary

How does Apollomics compare to Galectin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. UPB, IMRX, CAMP, STRO, and GALT

How does Apollomics compare to Upstream Bio?

Do institutionals and insiders have more ownership in UPB or APLM?

Is UPB or APLM more profitable?

Do analysts recommend UPB or APLM?

Which has more volatility and risk, UPB or APLM?

Which has stronger earnings and valuation, UPB or APLM?

Does the media refer more to UPB or APLM?

Summary

How does Apollomics compare to Immuneering?

Do institutionals & insiders have more ownership in APLM or IMRX?

Is APLM or IMRX more profitable?

Do analysts prefer APLM or IMRX?

Which has more risk and volatility, APLM or IMRX?

Which has higher valuation & earnings, APLM or IMRX?

Does the media prefer APLM or IMRX?

Summary

How does Apollomics compare to CAMP4 Therapeutics?

Do analysts prefer APLM or CAMP?

Is APLM or CAMP more profitable?

Does the media prefer APLM or CAMP?

Which has higher valuation & earnings, APLM or CAMP?

Which has more risk and volatility, APLM or CAMP?

Do institutionals & insiders have more ownership in APLM or CAMP?

Summary

How does Apollomics compare to Sutro Biopharma?

Which has more volatility & risk, STRO or APLM?

Does the media favor STRO or APLM?

Do insiders and institutionals hold more shares of STRO or APLM?

Do analysts rate STRO or APLM?

Which has higher earnings & valuation, STRO or APLM?

Is STRO or APLM more profitable?

Summary

How does Apollomics compare to Galectin Therapeutics?

Do analysts recommend GALT or APLM?

Is GALT or APLM more profitable?

Which has more risk & volatility, GALT or APLM?

Does the media favor GALT or APLM?

Do insiders and institutionals believe in GALT or APLM?

Which has higher earnings & valuation, GALT or APLM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools